Brandi M. Hudson

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index704citations137works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(95), Eosinophilic Disorders and Syndromes(70), Kruppel-like factors research(16), Asymmetric Synthesis and Catalysis(5), Computational Drug Discovery Methods(5)

Publications137 total

Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 Legend from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Table S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Table S4 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Table S3 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Dejan Maglic(26), Kamil Bruderek(26), B. Barry Touré(26), Songping Zhao(26), Roberto Valverde(26), Patrick J. O’Hearn(26), Demetri T. Moustakas(26), Heike Schönherr(26), Nastaran Gerami-Moayed(26), Alexander M. Taylor(26), Lindsey Foster(26), Hakan Günaydin(26), Pelin Ayaz(26), Dina A. Sharon(26), David E. Shaw(26), Donald A. Bergstrom(26), James Watters(26), Jessica B. Casaletto(26), Vivek Subbiah(25), Vaibhav Sahai(25)